Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Apple Restores Telegram to App Store After Content Policy Violation 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Telegram Restored on Apple App Store After Temporary Removal 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
CAMBRIDGE, Mass., April 09, 2018 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing neoantigen cancer vaccines, today announced upcoming presentations at the 2018 Annual Meeting of the American Association for Cancer Research (AACR 2018), taking place April 14-18, 2018 in Chicago, IL.
Poster 15: “Neoantigen identification using the ATLAS T cell profiling platform highlights the need to empirically define neoantigens”
Vaccines Session 1, Immunology Track
Sunday, April 15, 2018 from 1 pm to 5 pm CDT
Link to abstract
Poster 5718: “Ex vivo ATLAS-identification of neoantigens for personalized cancer immunotherapy in mouse melanoma”
Neoantigens in Cancer Session, Immunology Track
Wednesday, April 18, 2018 from 8 am to 12 pm CDT
Link to abstract
About Genocea Biosciences, Inc.
Genocea's mission is to help conquer cancer by designing and delivering targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, while also exploring partnership opportunities for general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea expects to begin clinical development of its first neoantigen cancer vaccine, GEN-009, in 2018. For more information, please visit www.genocea.com.
Contact:
Jennifer LaVin
207-360-0473
[email protected]
